Boehringer Ingelheim and Lilly Alliance has provided funding towards this educational programme. The Alliance has had no editorial input or influence on the agenda, collateral content of this meeting including the selection of speakers.
19th Annual Scientific Meeting
Treatments to improve cardiorenal outcomes in CKD. ‘Known knowns and known unknowns'
Online educational video available to view from Monday 7 October 2024
In association with:
The Cardiorenal Forum is pleased to be broadcasting this free, independent, online educational video for healthcare professionals as part of the activities for its 19th Annual Scientific Meeting.
Online educational video objectives
- To review recently published guidelines from KDIGO (Kidney Disease Improving Global Outcomes) for the Evaluation and Management of Chronic Kidney Disease (CKD).
- To consider that, despite multiple guidelines-based medical management, patients with CKD continue to experience residual cardiorenal risk.
- To look at the evidence for new drugs that have become available that could potentially transform CKD care and significantly improve clinical outcomes.
- To review the ‘known knowns and known unknowns’ of medical therapies proven to delay CKD progression.
- To assess whether we are moving towards acknowledged ‘Foundational drugs’ or ‘Pillars’ for early treatment of cardiorenal disease.
Is it for me?
This online educational video is aimed at healthcare professionals treating the cardiorenal patient, particularly those working in heart failure, cardiology, nephrology, diabetes, lipids, endocrinology, care of the elderly, general medicine, general practice, clinical pharmacy and allied disciplines. It will be free to register and view.
Accreditation
The Cardiorenal Forum will award 1 CPD credit for viewing this online educational video.
Academic endorsement
The Cardiorenal Forum is in academic partnership with KDIGO (Kidney Disease Improving Global Outcomes).
This year’s 19th Annual Scientific meeting of the Cardiorenal Forum has been endorsed by: The British Society for Heart Failure, The Irish Nephrology Society, KDIGO – Kidney Disease Improving Global Outcomes, The UK Kidney Association, and The UK Renal Pharmacy Group.
Treatments to improve cardiorenal outcomes in CKD. ‘Known knowns and known unknowns'
Boehringer-Ingelheim and Lilly Alliance has provided funding towards this educational programme. The Alliance has had no editorial input or influence on the agenda, collateral content of this meeting including the selection of speakers.
Programme: Treatments to improve cardiorenal outcomes in CKD. ‘Known knowns and known unknowns.’
The Cardiorenal Forum has developed the programme and chosen the speakers for this independent online educational video.
Running time: 30 minutes.
01:13 mins
Introduction
Chair: Professor William G. Herrington, Professor of Trials and Epidemiology of Kidney Disease, Oxford Population Health, University of Oxford; Honorary Consultant Nephrologist, Oxford Kidney Unit
21:14 mins
Pharmacotherapies proven to lower cardiorenal risk in chronic kidney disease
Dr Doreen Zhu, Nephrologist and Academic Clinical Lecturer, University of Oxford
12:00 mins
Discussion and Q&As
Moderator:
Dr Kaitlin Mayne
Participants:
Professor William G Herrington
Dr Doreen Zhu